Targeted therapies have significantly improved outcomes for specific subgroups of biliary tract cancer, with FGFR2 fusions and IDH1 mutations showing notable response rates.
Cholangiocarcinoma and Gallbladder Cancer Studies
Moving in Journal of hepatology, Gastroenterology, medRxiv, bioRxiv, Cancer Cell, Cancer Discovery, Gut, Nature Medicine.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Cholangiocarcinoma and Gallbladder Cancer Studies
Newest first · last 60 days
Integrating systemic therapy earlier in liver cancer shows promising but uncertain benefits, with advances in hepatocellular carcinoma and biliary tract cancers.
- Open access
A HER2-targeted quadruplet regimen achieved a 55% objective response rate in first-line treatment of HER2-positive unresectable biliary tract cancer, showing promising efficacy.
- Open access
Targeting multiple overlooked factors, the Heracles Protocol offers a comprehensive approach to make pancreatic ductal adenocarcinoma more treatable.
A PGE2-COX-2 feedback loop in PMN-MDSCs suppresses T cell antitumor activity in KRAS-mutant cholangiocarcinoma, revealing a potential therapeutic target.
- 1 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4